Neuralace Medical

Neuralace Medical is a San Diego-based neurotechnology company developing a minimally invasive subdural neurostimulation platform targeting drug-resistant epilepsy and chronic pain. At the core of their approach is a thin-film electrode array designed to conform precisely to the brain's cortical surface, enabling targeted stimulation with a high degree of spatial accuracy. Unlike traditional neurostimulation devices that often require more invasive surgical procedures, Neuralace's system is engineered to reduce the procedural burden on patients and clinicians alike. The technology represents a convergence of advanced materials science and neural engineering, positioning the company at the forefront of next-generation cortical interface design.

Neuralace Medical has secured $5 million in seed funding, providing an early capital foundation to advance its technology through research, development, and pre-clinical validation. The company is working toward clinical application in two significant therapeutic areas, drug-resistant epilepsy and chronic pain, both of which represent large unmet medical needs with limited satisfactory treatment options for a substantial patient population. While still in early stages, their minimally invasive approach is designed to lower the barrier to adoption among neurosurgeons and patients who may otherwise be reluctant to pursue more invasive intervention. Their progress reflects growing investor confidence in subdural stimulation as a viable and scalable treatment modality.

Neuralace Medical matters to the neurotech industry because it addresses a critical gap between the precision offered by invasive neural interfaces and the accessibility demanded by real-world clinical practice. Their thin-film subdural approach could serve as a model for how next-generation neurostimulation devices balance therapeutic efficacy with procedural safety and patient acceptability. As the brain-computer interface space matures beyond research applications into regulated medical devices, companies like Neuralace that prioritize clinical translatability are essential to realizing the field's broader potential. Their work in epilepsy and pain also opens pathways for expanding cortical stimulation into additional neurological and psychiatric indications over time.